TuisBMY • SWX
add
Bristol-Myers Squibb Co
Vorige sluiting
CHF 42,54
Jaarwisseling
CHF 42,54 - CHF 44,50
Markkapitalisasie
127,01 mjd USD
Gemiddelde volume
17,00
P/V-verhouding
-
Dividend-opbrengs
-
Primêre beurs
NYSE
In die nuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (USD) | Des. 2025info | J/J-verandering |
|---|---|---|
Inkomste | 12,50 mjd | 1,30% |
Bedryfskoste | 5,47 mjd | -13,56% |
Netto inkomste | 1,09 mjd | 1 409,72% |
Netto winsgrens | 8,69 | 1 398,28% |
Wins per aandeel | 1,26 | -24,55% |
EBITDA | 4,54 mjd | -2,17% |
Effektiewe belastingkoers | 26,12% | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (USD) | Des. 2025info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 10,67 mjd | -1,71% |
Totale bates | 90,04 mjd | -2,77% |
Totale aanspreeklikheid | 71,53 mjd | -6,14% |
Totale ekwiteit | 18,51 mjd | — |
Uitstaande aandele | 2,04 mjd | — |
Prys om te bespreek | 4,69 | — |
Opbrengs op bates | 9,42% | — |
Opbrengs op kapitaal | 13,01% | — |
Kontantvloei
Netto kontantverandering
| (USD) | Des. 2025info | J/J-verandering |
|---|---|---|
Netto inkomste | 1,09 mjd | 1 409,72% |
Kontant van bedrywe | 1,97 mjd | -55,53% |
Kontant van beleggings | -1,46 mjd | -643,88% |
Kontant van finansiering | -6,03 mjd | -267,17% |
Netto kontantverandering | -5,51 mjd | -324,45% |
Beskikbare kontantvloei | 669,62 m | -84,21% |
Meer oor
Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb, is an American multinational pharmaceutical company headquartered in Princeton, New Jersey. The company's primary products are apixaban for people with atrial fibrillation; nivolumab, used to treat certain types of cancer; lenalidomide, used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes; abatacept, used to treat autoimmune diseases such as rheumatoid arthritis; pomalidomide, an anti-cancer medication used for the treatment of multiple myeloma and AIDS-related Kaposi sarcoma; ipilimumab, to treat cancer; and luspatercept for the treatment of anemia in beta thalassemia and myelodysplastic syndromes. In 2024, 71% of the company's revenues came from the United States.
The company is ranked 94th on the Fortune 500 and 173rd on the Forbes Global 2000. Wikipedia
Gestig
1887
Webwerf
Werknemers
32 500